Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product

Executive Summary

The drug industry is not only worried about vulnerable patients, it's worried about vulnerable companies.

You may also be interested in...



PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded

FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.

PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded

FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.

PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement

Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS053154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel